

LABORATORY TEST REPORT

Name	: Miss. MADHAVI BANDA		
Sample ID	: A0787865		
Age/Gender	: 49 Years/Female	Reg. No	: 0312410290010
Referred by	: Dr. RUBY	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 29-Oct-2024 10:14 AM
Primary Sample	: Whole Blood	Received On	: 29-Oct-2024 01:13 PM
Sample Tested In	: Serum	Reported On	: 30-Oct-2024 02:50 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report



CLINICAL BIOCHEMISTRY

Test Name	Results	Units	Biological Reference Interval
HE4 with ROMA index			
CA125 - Cancer Marker (Method: CLIA)	39.9	U/mL	< 35.0
HE4-Human epididymis protein 4 (Method: ELISA)	62	pmol/L	Premenopausal: <= 70.0 Postmenopausal: <= 140
ROMA Value (Method: Calculated)	12.49	%	Premenopausal: > 11.4% = High Risk < 11.4% = Low Risk Postmenopausal > 29.9% = High Risk < 29.9% = Low Risk

- This assay is intended for use in women who are >18 years of age, have an ovarian mass with a planned surgery and not yet referred to an oncologist.
- The test should not be used in women with Rheumatoid factor concentration >250 IU/mL, patients previously treated for malignancy or presently on chemotherapy
- This assay is not intended to be used as a screening test to determine requirement of surgery in a patient
- All results should be correlated with clinical / radiological evaluation.

Comments

Risk of ovarian malignancy algorithm (ROMA) should be used as a supplement to the standard pre-surgical evaluation of a patient to assess likelihood of malignancy prior to surgery specially in those cases where presurgical evaluation does not indicate malignancy. Use of CA 125, HE4 & menopausal status to generate a numerical score helps in correlating likelihood of malignancy at the time of surgery in a patient presenting with adnexal mass.

*** End Of Report ***



Page 1 of 1
Dr. Vaishnavi
DR. VAISHNAVI
MD BIOCHEMISTRY